

CNK

& ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Bharat Parenterals Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2023 attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007

● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

4. The statement includes results of the following entities:
 - i. Innoxel Lifesciences Private Limited (Subsidiary)
 - ii. Varenyam Biolifesciences Private Limited (Subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Rachit Sheth

Partner

Membership No. 158289

Place: Vadodara

Date: 9th August, 2023

UDIN: 23158289BHAVXW4575



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

Sr. No.	Particular	Quarter Ended			Year Ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	A. Revenue from operations	6,991	5,097	2,609	21,798
	B. Other Income	210	31	154	1,174
	Total income	7,201	5,128	2,763	22,972
2	Expenses				
	A. Cost of materials consumed	4,613	3,771	2,466	14,607
	B. Purchase of Stock-in-Trade	14	2	131	116
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(580)	(791)	(999)	(975)
	D. Employee benefit expense	498	566	355	1,800
	E. Finance costs	89	80	25	219
	F. Depreciation, depletion and amortisation expense	158	144	154	588
	G. Other Expenses	1,403	927	475	4,263
	Total expenses	6,194	4,699	2,607	20,617
3	Total profit before tax	1,008	430	156	2,355
4	Tax expense				
	Current tax	321	276	49	840
	Deferred tax	(14)	(74)	(6)	(57)
	Short / (Excess) provision of tax in respect of earlier years				
	Total tax expenses	307	202	43	783
5	Net Profit / (loss) for period	701	227	112	1,571
6	Other comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Remeasurement of defined benefit obligation	1	29	(8)	6
	Income tax relating to Remeasurement of Defined benefit plans	(0)	(7)	2	(1)
	Other comprehensive Income for the year, net of taxes	1	22	(6)	4
7	Total Comprehensive Income for the period	702	249	106	1,576
	Net Profit attributable to:				
	Owners of the company	752	249	117	1,644
	Non Controlling Interest	(51)	(17)	(6)	(68)
	Other Comprehensive Income attributable to:				
	Owners of the company	1	22	(6)	4
	Non Controlling Interest	-	-	-	-
	Total Comprehensive Income for the period				
	Owners of the company	754	271	112	1,648
	Non Controlling Interest	(51)	(17)	(6)	(68)
8	Paid up Equity Share Capital (Face Value of Rs 10/- per share)				
9	Other Equity				577
10	Earnings per share				17,702
	Basic (Rs.)	13.03	4.24	2.03	28.04
	Diluted (Rs.)	13.03	4.24	2.03	28.04

See accompanying notes to the Financial Results

- The above unaudited financial results for the quarter ended June 30, 2023 have been duly reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on August 9, 2023.
- The above unaudited financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
- The Group has only one segment of activity, namely "Pharmaceuticals".
- The figures for the quarter ended 31st March, 2023 are the balancing figures between the audited figures in respect of full financial year and year to date figures upto third quarter of the respective financial years which were subject to limited review.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
 For Bharat Parenterals Limited



Bharat R. Desai
 DIN : 00552596
 Managing Director
 Place : Vadodara
 Date : 9th August 2023



Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Bharat Parenterals Limited ("the Company") for the quarter ended 30th June, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com


MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Rachit Sheth

Partner

Membership No. 158289

Date: 9th August, 2023

Place: Vadodara

UDIN: 23158289BHAVXV1039



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

Amount Rs. In Lakhs

Sr. No.	Particular	Quarter Ended			Year Ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	A. Revenue from operations	6,991	5,097	2,609	21,798
	B. Other Income	286	696	154	1,884
	Total income	7,277	5,793	2,763	23,682
2	Expenses				
	A. Cost of materials consumed	4,613	3,771	2,466	14,607
	B. Purchase of Stock-in-Trade	14	2	131	116
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(580)	(791)	(999)	(975)
	D. Employee benefit expense	424	490	352	1,693
	E. Finance costs	88	80	25	219
	F. Depreciation, depletion and amortisation expense	151	143	154	585
	G. Other Expenses	1,371	966	465	4,220
	Total expenses	6,081	4,661	2,595	20,465
3	Total profit before tax	1,196	1,132	168	3,217
4	Tax expense				
	Current tax	321	276	49	840
	Deferred tax	(14)	(74)	(6)	(57)
	Short / (Excess) provision of tax in respect of earlier years	-	-	-	-
	Total tax expenses	307	202	43	783
5	Net Profit / (loss) for period	889	929	125	2,434
6	Other comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Remeasurement of defined benefit obligation	1	29	(8)	6
	Income tax relating to Remeasurement of Defined benefit plans	(0)	(7)	2	(1)
	Other comprehensive Income for the year, net of taxes	1	22	(6)	4
7	Total Comprehensive Income for the period	891	951	119	2,438
8	Paid up Equity Share Capital (Face Value of Rs 10/- per share)				577
9	Other Equity				18,529
10	Earnings per share				
	Basic (Rs.)	15.40	16.19	2.16	42.40
	Diluted (Rs.)	15.40	16.19	2.16	42.40

See accompanying notes to the Financial Results

- The above unaudited financial results for the quarter ended June 30, 2023 have been duly reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on August 9, 2023.
- The Company has only one segment of activity, namely "Pharmaceuticals."
- The figures for the quarter ended 31st March, 2023 are the balancing figures between the audited figures in respect of full financial year and year to date figures upto third quarter of the respective financial years which were subject to limited review.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
DIN : 00552596
Managing Director
Place : Vadodara
Date : 9th August 2023

